The increasing prevalence of polymyalgia rheumatica among the elderly population is boosting the adoption of polymyalgia rheumatica treatment to efficiently control painful myalgia. Furthermore, the ...

According to a recent report by Market.us, the Global Polymyalgia Rheumatica Treatment Market size is expected to be worth around USD 318.4 Million by 2033 from USD 199.2 Million in 2023, growing at a ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved sarilumab for the treatment of polymyalgia rheumatica in adults who have experienced an ...

Please provide your email address to receive an email when new articles are posted on . Patients were more likely to achieve sustained remission with sarilumab vs. placebo. The most common adverse ...

In this article, Lally and colleagues present the results of an open-label trial of the anti-interleukin (IL)-6 receptor agent tocilizumab in 10 patients with isolated polymyalgia rheumatica (PMR).

DEAR DR. ROACH: I was recently diagnosed with polymyalgia rheumatica after weeks of intense muscle pain. I’m a 67-year-old female in otherwise good health. My doctor prescribed prednisone, which ...

"Polymyalgia Rheumatica Pipeline Analysis"DelveInsight's,“Polymyalgia Rheumatica – Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in ...

The in-depth research report on Polymyalgia Rheumatica Treatment Market added to its huge repository by DBMR provides imprehensive and all aspects of market research. The market insights of this ...

Polymyalgia rheumatica (PMR) is an inflammatory disorder that causes severe muscle pain, muscle stiffness, muscle spasms and cramping on both sides of the body, particularly in the shoulders, neck, ...

PORTLAND, Ore.--(BUSINESS WIRE)--Sparrow Pharmaceuticals today announced that it presented new data from its ongoing Phase 2 clinical trial of its HSD-1 inhibitor, clofutriben (referred to SPI-62 in ...

The US Food and Drug Administration (FDA) approved sarilumab (Kevzara) today for the treatment of polymyalgia rheumatica (PMR) in adults who have had an inadequate response to corticosteroids or could ...